產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-BARD1抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-BARD1抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-BARD1
Cat. Number:
Anti-BARD1抗體KL-4291R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
BRCA1 Associated RINGAnti-BARD1抗體 Domain gene 1 (BARD1) interacts with the N terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N terminal RING motif and the C terminal BRCT domain. The RING motif is a cysteine rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer. BARD1 also plays a role in mediating apoptotic stress and p53 dependent.
Also known as:
BARD-1; Bard1; Bard 1; Anti-BARD1抗體BARD1_HUMAN; BRCA1 associated RING domain 1; BRCA1 associated RING domain gene 1; BRCA1 associated RING domain protein 1; BRCA1-associated RING domain protein 1.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, .
●
Immunogen: KLH conjugated synthetic peptide derived from human BARD1.
●
Predicted Molecular Weight: 85kDa.
Storage:
Shipped at 4℃, Anti-BARD1抗體Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications.
Optimal working Anti-BARD1抗體dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working Anti-BARD1抗體dilutions must be determined by the end user.
kl782Hu01 碳酸酐酶Ⅱ(CA2)多克隆抗體 Polyclonal Antibody to Carbonic Anhydrase II (CA2)
kl783Hu01 補(bǔ)體因子P(CFP)多克隆抗體 Polyclonal Antibody to Complement Factor P (CFP)
kl785Hu01 腎損傷分子1(Kim1)多克隆抗體 Polyclonal Antibody to Kidney Injury Molecule 1 (Kim1)
kl785Mu01 腎損傷分子1(Kim1)多克隆抗體 Polyclonal Antibody to Kidney Injury Molecule 1 (Kim1)
kl785Ra01 腎損傷分子1(Kim1)多克隆抗體 Polyclonal Antibody to Kidney Injury Molecule 1 (Kim1)
kl786Hu01 纖維膠凝蛋白1(FCN1)多克隆抗體 Polyclonal Antibody to Ficolin 1 (FCN1)
kl786Mu01 纖維膠凝蛋白1(FCN1)多克隆抗體 Polyclonal Antibody to Ficolin 1 (FCN1)
kl788Hu01 細(xì)胞程序性死亡蛋白1配體1(PDCD1LG1)多克隆抗體 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDCD1LG1)
kl788Mu01 細(xì)胞程序性死亡蛋白1配體1(PDCD1LG1)多克隆抗體 Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDCD1LG1)
kl791Mu01 骨粘連蛋白(ON)多克隆抗體 Polyclonal Antibody to Osteonectin (ON)
kl791Ra01 骨粘連蛋白(ON)多克隆抗體 Polyclonal Antibody to Osteonectin (ON)
kl792Hu01 拓?fù)洚悩?gòu)酶Ⅱ(TOP2)多克隆抗體 Polyclonal Antibody to Topoisomerase II (TOP2)
kl794Hu01 周期素依賴性激酶抑制因子2A(CDKN2A)多克隆抗體 Polyclonal Antibody to Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)
kl794Mu01 周期素依賴性激酶抑制因子2A(CDKN2A)多克隆抗體 Polyclonal Antibody to Cyclin Dependent Kinase Inhibitor 2A (CDKN2A)
kl796Hu01 神經(jīng)肽S(NPS)多克隆抗體 Polyclonal Antibody to Neuropeptide S (NPS)
kl796Mu01 神經(jīng)肽S(NPS)多克隆抗體 Polyclonal Antibody to Neuropeptide S (NPS)
kl796Ra01 神經(jīng)肽S(NPS)多克隆抗體 Polyclonal Antibody to Neuropeptide S (NPS)
kl797Hu01 血管緊張素原(AGT)多克隆抗體 Polyclonal Antibody to Angiotensinogen (AGT)
kl797Mu01 血管緊張素原(AGT)多克隆抗體 Polyclonal Antibody to Angiotensinogen (AGT)
